Cancer Network shared on LinkedIn:
“Experts in multiple myeloma look to the future treatment landscape and discuss exciting updates presented at the 2024 ASCO Annual Meeting, highlighting belantamab mafodotin and combination therapies.”
Source: Cancer Network/LinkedIn